Global Cholera Vaccine
Global Cholera Vaccine

Cholera Vaccine Comprehensive Study by Type (Shanchol, Dukoral, Vaxchora, Others), End-users (Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others), Serogroup (Serogroup O1, Serogroup O139) Players and Region - Global Market Outlook to 2025

Cholera Vaccine Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jun 2020 Edition 238 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Cholera Vaccine Market Definition
Cholera is a bacterial disease caused by the ingestion of food or water contaminated with the bacterium Vibrio cholerae, which can lead to dehydration and even death if untreated. According to the World Health Organization (WHO) each year there are 1.3 million to 4.0 million cases of cholera, and 21 000 to 143 000 deaths worldwide due to cholera. Cholera vaccine is a sterile suspension of equal parts of Ogawa and Inaba serotypes of killed Vibrio cholerae (V. comma) in buffered sodium chloride injection and that can be injected intracutaneously (intradermally), subcutaneously or intramuscularly. In January 2020, Emergent BioSolutions Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the approval of the company’s single-dose oral cholera vaccine, Vaxchora (Cholera Vaccine, Live, Oral).

The market study is broken down by Type (Shanchol, Dukoral, Vaxchora and Others) and major geographies with country level splits.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Cholera Vaccine market throughout the predicted period.

PaxVax, Inc. (United Sates), Valneva SE (France), Emergent BioSolutions, Inc. (United States), Astellas Pharma, Inc. (Japan), Sanofi S.A. (France), Eubiologics Co., Ltd. (South Korea), Johnson & Johnson (United States), Celldex Therapeutics, Inc. (United States), Merck & Co., Inc. (United States) and GlaxoSmithKline plc. (United Kingdom) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Cholera Vaccine market by Type, Application and Region.

On the basis of geography, the market of Cholera Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Hospital will boost the Cholera Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Serogroup, the sub-segment i.e. Serogroup O1 will boost the Cholera Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In October 2018, Emergent BioSolutions Inc. has announced that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases.


Market Trend
  • Increased Research and Development Activities
  • Rising Government Initiatives for Development of Vaccines

Market Drivers
  • Increasing Number of Cholera Patients Worldwide
  • Rise in the Hospitals and Clinics
  • Growing Healthcare Infrastructure in Emerging Economies

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Huge Investments by Major Players
  • Robust Increase in the Distribution Channels

Restraints
  • High Cost Associated with the Development of the Vaccine
  • Changing Structure of the Viruses

Challenges
  • Stringent Government Rules and Regulations


Key Target Audience
Cholera Vaccine Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Shanchol
  • Dukoral
  • Vaxchora
  • Others
By End-users
  • Hospital
  • Research & Academic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Others

By Serogroup
  • Serogroup O1
  • Serogroup O139

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cholera Patients Worldwide
      • 3.2.2. Rise in the Hospitals and Clinics
      • 3.2.3. Growing Healthcare Infrastructure in Emerging Economies
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. Rising Government Initiatives for Development of Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cholera Vaccine, by Type, End-users, Serogroup and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Cholera Vaccine (Value)
      • 5.2.1. Global Cholera Vaccine by: Type (Value)
        • 5.2.1.1. Shanchol
        • 5.2.1.2. Dukoral
        • 5.2.1.3. Vaxchora
        • 5.2.1.4. Others
      • 5.2.2. Global Cholera Vaccine by: End-users (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Research & Academic Laboratories
        • 5.2.2.3. Pharmaceutical & Biotechnology Companies
        • 5.2.2.4. Others
      • 5.2.3. Global Cholera Vaccine by: Serogroup (Value)
        • 5.2.3.1. Serogroup O1
        • 5.2.3.2. Serogroup O139
      • 5.2.4. Global Cholera Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cholera Vaccine (Volume)
      • 5.3.1. Global Cholera Vaccine by: Type (Volume)
        • 5.3.1.1. Shanchol
        • 5.3.1.2. Dukoral
        • 5.3.1.3. Vaxchora
        • 5.3.1.4. Others
      • 5.3.2. Global Cholera Vaccine by: End-users (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Research & Academic Laboratories
        • 5.3.2.3. Pharmaceutical & Biotechnology Companies
        • 5.3.2.4. Others
      • 5.3.3. Global Cholera Vaccine by: Serogroup (Volume)
        • 5.3.3.1. Serogroup O1
        • 5.3.3.2. Serogroup O139
      • 5.3.4. Global Cholera Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Cholera Vaccine (Price)
      • 5.4.1. Global Cholera Vaccine by: Type (Price)
  • 6. Cholera Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. PaxVax, Inc. (United Sates)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Valneva SE (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Emergent BioSolutions, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astellas Pharma, Inc. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eubiologics Co., Ltd. (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celldex Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co., Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cholera Vaccine Sale, by Type, End-users, Serogroup and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Cholera Vaccine (Value)
      • 7.2.1. Global Cholera Vaccine by: Type (Value)
        • 7.2.1.1. Shanchol
        • 7.2.1.2. Dukoral
        • 7.2.1.3. Vaxchora
        • 7.2.1.4. Others
      • 7.2.2. Global Cholera Vaccine by: End-users (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Research & Academic Laboratories
        • 7.2.2.3. Pharmaceutical & Biotechnology Companies
        • 7.2.2.4. Others
      • 7.2.3. Global Cholera Vaccine by: Serogroup (Value)
        • 7.2.3.1. Serogroup O1
        • 7.2.3.2. Serogroup O139
      • 7.2.4. Global Cholera Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cholera Vaccine (Volume)
      • 7.3.1. Global Cholera Vaccine by: Type (Volume)
        • 7.3.1.1. Shanchol
        • 7.3.1.2. Dukoral
        • 7.3.1.3. Vaxchora
        • 7.3.1.4. Others
      • 7.3.2. Global Cholera Vaccine by: End-users (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Research & Academic Laboratories
        • 7.3.2.3. Pharmaceutical & Biotechnology Companies
        • 7.3.2.4. Others
      • 7.3.3. Global Cholera Vaccine by: Serogroup (Volume)
        • 7.3.3.1. Serogroup O1
        • 7.3.3.2. Serogroup O139
      • 7.3.4. Global Cholera Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Cholera Vaccine (Price)
      • 7.4.1. Global Cholera Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cholera Vaccine: by Type(USD Million)
  • Table 2. Cholera Vaccine Shanchol , by Region USD Million (2014-2019)
  • Table 3. Cholera Vaccine Dukoral , by Region USD Million (2014-2019)
  • Table 4. Cholera Vaccine Vaxchora , by Region USD Million (2014-2019)
  • Table 5. Cholera Vaccine Others , by Region USD Million (2014-2019)
  • Table 6. Cholera Vaccine: by End-users(USD Million)
  • Table 7. Cholera Vaccine Hospital , by Region USD Million (2014-2019)
  • Table 8. Cholera Vaccine Research & Academic Laboratories , by Region USD Million (2014-2019)
  • Table 9. Cholera Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2014-2019)
  • Table 10. Cholera Vaccine Others , by Region USD Million (2014-2019)
  • Table 11. Cholera Vaccine: by Serogroup(USD Million)
  • Table 12. Cholera Vaccine Serogroup O1 , by Region USD Million (2014-2019)
  • Table 13. Cholera Vaccine Serogroup O139 , by Region USD Million (2014-2019)
  • Table 14. South America Cholera Vaccine, by Country USD Million (2014-2019)
  • Table 15. South America Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 16. South America Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 17. South America Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 18. Brazil Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 19. Brazil Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 20. Brazil Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 21. Argentina Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 22. Argentina Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 23. Argentina Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 24. Rest of South America Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 25. Rest of South America Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 26. Rest of South America Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 27. Asia Pacific Cholera Vaccine, by Country USD Million (2014-2019)
  • Table 28. Asia Pacific Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 29. Asia Pacific Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 30. Asia Pacific Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 31. China Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 32. China Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 33. China Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 34. Japan Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 35. Japan Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 36. Japan Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 37. India Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 38. India Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 39. India Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 40. South Korea Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 41. South Korea Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 42. South Korea Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 43. Taiwan Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 44. Taiwan Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 45. Taiwan Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 46. Australia Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 47. Australia Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 48. Australia Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 52. Europe Cholera Vaccine, by Country USD Million (2014-2019)
  • Table 53. Europe Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 54. Europe Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 55. Europe Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 56. Germany Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 57. Germany Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 58. Germany Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 59. France Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 60. France Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 61. France Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 62. Italy Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 63. Italy Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 64. Italy Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 65. United Kingdom Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 66. United Kingdom Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 67. United Kingdom Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 68. Netherlands Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 69. Netherlands Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 70. Netherlands Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 71. Rest of Europe Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 72. Rest of Europe Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 73. Rest of Europe Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 74. MEA Cholera Vaccine, by Country USD Million (2014-2019)
  • Table 75. MEA Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 76. MEA Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 77. MEA Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 78. Middle East Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 79. Middle East Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 80. Middle East Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 81. Africa Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 82. Africa Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 83. Africa Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 84. North America Cholera Vaccine, by Country USD Million (2014-2019)
  • Table 85. North America Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 86. North America Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 87. North America Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 88. United States Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 89. United States Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 90. United States Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 91. Canada Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 92. Canada Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 93. Canada Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 94. Mexico Cholera Vaccine, by Type USD Million (2014-2019)
  • Table 95. Mexico Cholera Vaccine, by End-users USD Million (2014-2019)
  • Table 96. Mexico Cholera Vaccine, by Serogroup USD Million (2014-2019)
  • Table 97. Cholera Vaccine Sales: by Type(K Units)
  • Table 98. Cholera Vaccine Sales Shanchol , by Region K Units (2014-2019)
  • Table 99. Cholera Vaccine Sales Dukoral , by Region K Units (2014-2019)
  • Table 100. Cholera Vaccine Sales Vaxchora , by Region K Units (2014-2019)
  • Table 101. Cholera Vaccine Sales Others , by Region K Units (2014-2019)
  • Table 102. Cholera Vaccine Sales: by End-users(K Units)
  • Table 103. Cholera Vaccine Sales Hospital , by Region K Units (2014-2019)
  • Table 104. Cholera Vaccine Sales Research & Academic Laboratories , by Region K Units (2014-2019)
  • Table 105. Cholera Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Units (2014-2019)
  • Table 106. Cholera Vaccine Sales Others , by Region K Units (2014-2019)
  • Table 107. Cholera Vaccine Sales: by Serogroup(K Units)
  • Table 108. Cholera Vaccine Sales Serogroup O1 , by Region K Units (2014-2019)
  • Table 109. Cholera Vaccine Sales Serogroup O139 , by Region K Units (2014-2019)
  • Table 110. South America Cholera Vaccine Sales, by Country K Units (2014-2019)
  • Table 111. South America Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 112. South America Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 113. South America Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 114. Brazil Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 115. Brazil Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 116. Brazil Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 117. Argentina Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 118. Argentina Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 119. Argentina Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 120. Rest of South America Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 121. Rest of South America Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 122. Rest of South America Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 123. Asia Pacific Cholera Vaccine Sales, by Country K Units (2014-2019)
  • Table 124. Asia Pacific Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 125. Asia Pacific Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 126. Asia Pacific Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 127. China Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 128. China Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 129. China Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 130. Japan Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 131. Japan Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 132. Japan Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 133. India Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 134. India Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 135. India Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 136. South Korea Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 137. South Korea Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 138. South Korea Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 139. Taiwan Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 140. Taiwan Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 141. Taiwan Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 142. Australia Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 143. Australia Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 144. Australia Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 145. Rest of Asia-Pacific Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 146. Rest of Asia-Pacific Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 147. Rest of Asia-Pacific Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 148. Europe Cholera Vaccine Sales, by Country K Units (2014-2019)
  • Table 149. Europe Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 150. Europe Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 151. Europe Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 152. Germany Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 153. Germany Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 154. Germany Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 155. France Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 156. France Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 157. France Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 158. Italy Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 159. Italy Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 160. Italy Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 161. United Kingdom Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 162. United Kingdom Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 163. United Kingdom Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 164. Netherlands Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 165. Netherlands Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 166. Netherlands Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 167. Rest of Europe Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 168. Rest of Europe Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 169. Rest of Europe Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 170. MEA Cholera Vaccine Sales, by Country K Units (2014-2019)
  • Table 171. MEA Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 172. MEA Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 173. MEA Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 174. Middle East Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 175. Middle East Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 176. Middle East Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 177. Africa Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 178. Africa Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 179. Africa Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 180. North America Cholera Vaccine Sales, by Country K Units (2014-2019)
  • Table 181. North America Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 182. North America Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 183. North America Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 184. United States Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 185. United States Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 186. United States Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 187. Canada Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 188. Canada Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 189. Canada Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 190. Mexico Cholera Vaccine Sales, by Type K Units (2014-2019)
  • Table 191. Mexico Cholera Vaccine Sales, by End-users K Units (2014-2019)
  • Table 192. Mexico Cholera Vaccine Sales, by Serogroup K Units (2014-2019)
  • Table 193. Cholera Vaccine: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Cholera Vaccine: by Type(USD Million)
  • Table 205. Cholera Vaccine Shanchol , by Region USD Million (2020-2025)
  • Table 206. Cholera Vaccine Dukoral , by Region USD Million (2020-2025)
  • Table 207. Cholera Vaccine Vaxchora , by Region USD Million (2020-2025)
  • Table 208. Cholera Vaccine Others , by Region USD Million (2020-2025)
  • Table 209. Cholera Vaccine: by End-users(USD Million)
  • Table 210. Cholera Vaccine Hospital , by Region USD Million (2020-2025)
  • Table 211. Cholera Vaccine Research & Academic Laboratories , by Region USD Million (2020-2025)
  • Table 212. Cholera Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2020-2025)
  • Table 213. Cholera Vaccine Others , by Region USD Million (2020-2025)
  • Table 214. Cholera Vaccine: by Serogroup(USD Million)
  • Table 215. Cholera Vaccine Serogroup O1 , by Region USD Million (2020-2025)
  • Table 216. Cholera Vaccine Serogroup O139 , by Region USD Million (2020-2025)
  • Table 217. South America Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 218. South America Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 219. South America Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 220. South America Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 221. Brazil Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 222. Brazil Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 223. Brazil Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 224. Argentina Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 225. Argentina Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 226. Argentina Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 227. Rest of South America Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 228. Rest of South America Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 229. Rest of South America Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 230. Asia Pacific Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 231. Asia Pacific Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 232. Asia Pacific Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 233. Asia Pacific Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 234. China Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 235. China Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 236. China Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 237. Japan Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 238. Japan Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 239. Japan Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 240. India Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 241. India Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 242. India Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 243. South Korea Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 244. South Korea Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 245. South Korea Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 246. Taiwan Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 247. Taiwan Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 248. Taiwan Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 249. Australia Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 250. Australia Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 251. Australia Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 252. Rest of Asia-Pacific Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 253. Rest of Asia-Pacific Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 254. Rest of Asia-Pacific Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 255. Europe Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 256. Europe Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 257. Europe Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 258. Europe Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 259. Germany Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 260. Germany Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 261. Germany Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 262. France Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 263. France Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 264. France Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 265. Italy Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 266. Italy Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 267. Italy Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 268. United Kingdom Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 269. United Kingdom Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 270. United Kingdom Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 271. Netherlands Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 272. Netherlands Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 273. Netherlands Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 274. Rest of Europe Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 275. Rest of Europe Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 276. Rest of Europe Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 277. MEA Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 278. MEA Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 279. MEA Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 280. MEA Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 281. Middle East Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 282. Middle East Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 283. Middle East Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 284. Africa Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 285. Africa Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 286. Africa Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 287. North America Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 288. North America Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 289. North America Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 290. North America Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 291. United States Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 292. United States Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 293. United States Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 294. Canada Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 295. Canada Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 296. Canada Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 297. Mexico Cholera Vaccine, by Type USD Million (2020-2025)
  • Table 298. Mexico Cholera Vaccine, by End-users USD Million (2020-2025)
  • Table 299. Mexico Cholera Vaccine, by Serogroup USD Million (2020-2025)
  • Table 300. Cholera Vaccine Sales: by Type(K Units)
  • Table 301. Cholera Vaccine Sales Shanchol , by Region K Units (2020-2025)
  • Table 302. Cholera Vaccine Sales Dukoral , by Region K Units (2020-2025)
  • Table 303. Cholera Vaccine Sales Vaxchora , by Region K Units (2020-2025)
  • Table 304. Cholera Vaccine Sales Others , by Region K Units (2020-2025)
  • Table 305. Cholera Vaccine Sales: by End-users(K Units)
  • Table 306. Cholera Vaccine Sales Hospital , by Region K Units (2020-2025)
  • Table 307. Cholera Vaccine Sales Research & Academic Laboratories , by Region K Units (2020-2025)
  • Table 308. Cholera Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Units (2020-2025)
  • Table 309. Cholera Vaccine Sales Others , by Region K Units (2020-2025)
  • Table 310. Cholera Vaccine Sales: by Serogroup(K Units)
  • Table 311. Cholera Vaccine Sales Serogroup O1 , by Region K Units (2020-2025)
  • Table 312. Cholera Vaccine Sales Serogroup O139 , by Region K Units (2020-2025)
  • Table 313. South America Cholera Vaccine Sales, by Country K Units (2020-2025)
  • Table 314. South America Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 315. South America Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 316. South America Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 317. Brazil Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 318. Brazil Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 319. Brazil Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 320. Argentina Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 321. Argentina Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 322. Argentina Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 323. Rest of South America Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 324. Rest of South America Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 325. Rest of South America Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 326. Asia Pacific Cholera Vaccine Sales, by Country K Units (2020-2025)
  • Table 327. Asia Pacific Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 328. Asia Pacific Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 329. Asia Pacific Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 330. China Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 331. China Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 332. China Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 333. Japan Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 334. Japan Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 335. Japan Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 336. India Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 337. India Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 338. India Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 339. South Korea Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 340. South Korea Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 341. South Korea Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 342. Taiwan Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 343. Taiwan Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 344. Taiwan Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 345. Australia Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 346. Australia Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 347. Australia Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 348. Rest of Asia-Pacific Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 349. Rest of Asia-Pacific Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 350. Rest of Asia-Pacific Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 351. Europe Cholera Vaccine Sales, by Country K Units (2020-2025)
  • Table 352. Europe Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 353. Europe Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 354. Europe Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 355. Germany Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 356. Germany Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 357. Germany Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 358. France Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 359. France Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 360. France Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 361. Italy Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 362. Italy Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 363. Italy Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 364. United Kingdom Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 365. United Kingdom Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 366. United Kingdom Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 367. Netherlands Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 368. Netherlands Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 369. Netherlands Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 370. Rest of Europe Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 371. Rest of Europe Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 372. Rest of Europe Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 373. MEA Cholera Vaccine Sales, by Country K Units (2020-2025)
  • Table 374. MEA Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 375. MEA Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 376. MEA Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 377. Middle East Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 378. Middle East Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 379. Middle East Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 380. Africa Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 381. Africa Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 382. Africa Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 383. North America Cholera Vaccine Sales, by Country K Units (2020-2025)
  • Table 384. North America Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 385. North America Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 386. North America Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 387. United States Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 388. United States Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 389. United States Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 390. Canada Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 391. Canada Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 392. Canada Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 393. Mexico Cholera Vaccine Sales, by Type K Units (2020-2025)
  • Table 394. Mexico Cholera Vaccine Sales, by End-users K Units (2020-2025)
  • Table 395. Mexico Cholera Vaccine Sales, by Serogroup K Units (2020-2025)
  • Table 396. Cholera Vaccine: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cholera Vaccine: by Type USD Million (2014-2019)
  • Figure 5. Global Cholera Vaccine: by End-users USD Million (2014-2019)
  • Figure 6. Global Cholera Vaccine: by Serogroup USD Million (2014-2019)
  • Figure 7. South America Cholera Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Cholera Vaccine Share (%), by Country
  • Figure 9. Europe Cholera Vaccine Share (%), by Country
  • Figure 10. MEA Cholera Vaccine Share (%), by Country
  • Figure 11. North America Cholera Vaccine Share (%), by Country
  • Figure 12. Global Cholera Vaccine: by Type K Units (2014-2019)
  • Figure 13. Global Cholera Vaccine: by End-users K Units (2014-2019)
  • Figure 14. Global Cholera Vaccine: by Serogroup K Units (2014-2019)
  • Figure 15. South America Cholera Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Cholera Vaccine Share (%), by Country
  • Figure 17. Europe Cholera Vaccine Share (%), by Country
  • Figure 18. MEA Cholera Vaccine Share (%), by Country
  • Figure 19. North America Cholera Vaccine Share (%), by Country
  • Figure 20. Global Cholera Vaccine: by Type USD/Units (2014-2019)
  • Figure 21. Global Cholera Vaccine share by Players 2019 (%)
  • Figure 22. Global Cholera Vaccine share by Players (Top 3) 2019(%)
  • Figure 23. Global Cholera Vaccine share by Players (Top 5) 2019(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. PaxVax, Inc. (United Sates) Revenue, Net Income and Gross profit
  • Figure 26. PaxVax, Inc. (United Sates) Revenue: by Geography 2019
  • Figure 27. Valneva SE (France) Revenue, Net Income and Gross profit
  • Figure 28. Valneva SE (France) Revenue: by Geography 2019
  • Figure 29. Emergent BioSolutions, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Emergent BioSolutions, Inc. (United States) Revenue: by Geography 2019
  • Figure 31. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2019
  • Figure 33. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi S.A. (France) Revenue: by Geography 2019
  • Figure 35. Eubiologics Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. Eubiologics Co., Ltd. (South Korea) Revenue: by Geography 2019
  • Figure 37. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson & Johnson (United States) Revenue: by Geography 2019
  • Figure 39. Celldex Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Celldex Therapeutics, Inc. (United States) Revenue: by Geography 2019
  • Figure 41. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 43. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2019
  • Figure 45. Global Cholera Vaccine: by Type USD Million (2020-2025)
  • Figure 46. Global Cholera Vaccine: by End-users USD Million (2020-2025)
  • Figure 47. Global Cholera Vaccine: by Serogroup USD Million (2020-2025)
  • Figure 48. South America Cholera Vaccine Share (%), by Country
  • Figure 49. Asia Pacific Cholera Vaccine Share (%), by Country
  • Figure 50. Europe Cholera Vaccine Share (%), by Country
  • Figure 51. MEA Cholera Vaccine Share (%), by Country
  • Figure 52. North America Cholera Vaccine Share (%), by Country
  • Figure 53. Global Cholera Vaccine: by Type K Units (2020-2025)
  • Figure 54. Global Cholera Vaccine: by End-users K Units (2020-2025)
  • Figure 55. Global Cholera Vaccine: by Serogroup K Units (2020-2025)
  • Figure 56. South America Cholera Vaccine Share (%), by Country
  • Figure 57. Asia Pacific Cholera Vaccine Share (%), by Country
  • Figure 58. Europe Cholera Vaccine Share (%), by Country
  • Figure 59. MEA Cholera Vaccine Share (%), by Country
  • Figure 60. North America Cholera Vaccine Share (%), by Country
  • Figure 61. Global Cholera Vaccine: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • PaxVax, Inc. (United Sates)
  • Valneva SE (France)
  • Emergent BioSolutions, Inc. (United States)
  • Astellas Pharma, Inc. (Japan)
  • Sanofi S.A. (France)
  • Eubiologics Co., Ltd. (South Korea)
  • Johnson & Johnson (United States)
  • Celldex Therapeutics, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • GlaxoSmithKline plc. (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation